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Abstract
The development of anti-virals has blunted the AIDS epidemic in the Western world but globally
the epidemic has not been curtailed. Standard vaccines have not worked, and attenuated vaccines
are not being developed because of safety concerns. Interest in attenuated vaccines has centered
on isolated cases of patients infected with HIV-1 containing a deleted nef  gene. Nef is a
multifunctional accessory protein that is necessary for full HIV-1 virulence. Unfortunately, some
patients infected with the nef-deleted virus eventually lose their CD4+ T cells to levels indicating
progression to AIDS.
This renders the possibility of an attenuated HIV-1 based solely on a deleted nef remote. In this
review we discuss the knowledge gained both from the study of these patients and from in vitro
investigations of Nef function to assess the possibility of developing new anti-HIV-1 drugs based on
Nef. Specifically, we consider CD4 downregulation, major histocompatibility complex I
downregulation, Pak2 activation, and enhancement of virion infectivity. We also consider the
recent proposal that simian immunodeficiency viruses are non-pathogenic in their hosts because
they have Nefs that downregulate CD3, but HIV-1 is pathogenic because its Nef fails to
downregulate CD3. The possibility of incorporating the CD3 downregulation function into HIV-1
Nef as a therapeutic option is also considered. Finally, we conclude that inhibiting the CD4
downregulation function is the most promising Nef-targeted approach for developing a new anti-
viral as a contribution to combating AIDS.
Introduction
The brutal attack on humanity by HIV-1 has proven to be
distressingly difficult to counter. The best results at blunt-
ing the epidemic have been the development of anti-ret-
rovirals (ARVs) that inhibit crucial HIV-1 functions.
Unfortunately, the unique ability of HIV-1 to mutate and
adapt [1,2] requires multiple drug treatments that are lim-
ited in their application by their side effects and their
expense. Topically applied microbicides offer the possibil-
ity of prevention, but similar problems of toxicity,
expense, and effective application apply here as well as
with ARVs [3,4]. Vaccines have been a total failure and
future prospects are dim [5-8].
Well into the third decade of HIV-1 research the likeli-
hood of finding an Achilles' heel for HIV-1 is remote. The
virus is too highly adapted from its successful 70 year con-
test with the human immune system [9,10]. Accumulat-
ing small victories are the probable long term course for
significantly curtailing the epidemic. Effective microbi-
cides are desperately needed for vaginal pre-exposure
prophylaxis and post-exposure prophylaxis. New ARVs
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that inhibit an increasing number of viral processes are
critical for treating already infected individuals. ARVs are
potentially useful in prophylaxis as well. In this case topi-
cally applied drugs would ideally be different from drugs
used for treating HIV-1 since topical application could
lead to resistant strains of HIV-1 [3,4]. Therefore, all pos-
sible targets for countering HIV-1 need to be considered.
Given its central role in HIV pathogenesis, in this article
we consider Nef as a potential anti-viral target for prevent-
ing or at least delaying pathogenesis.
Ironically, the overwhelming focus for a Nef-based thera-
peutic intervention has been the investigation of a nef-
deleted attenuated virus vaccine. This interest resulted
from a small number of cases of long term non-progres-
sors (LTNP) whose viruses have irretrievable deletions in
the  nef  gene [11-14]. Unfortunately, some individuals
infected with the nef-deleted virus are slow progressors
(SP) rendering a nef-deleted attenuated vaccine too dan-
gerous. We will not review this aspect of the Nef field in
detail since an excellent review has been recently pub-
lished on the most important of these cases- the Sydney
Blood Bank Cohort (SBBC) [15]. We will discuss several
aspects of SBBC and other cases that shed light on the role
of Nef in the development of HIV-1 disease.
The lack of disease progression in patients whose HIV-1s
are  nef-deleted, defines Nef as a pathogenic factor.
Whether Nef acts as a generalized enabler of high levels of
replication or is directly pathogenic remains unresolved.
In either case it would seem logical to investigate blocking
Nef function in order to lessen the severity of HIV-1 dis-
ease. Though the idea of Nef as a target for drug interven-
tion in HIV-1 disease has rarely been considered [16,17],
Betzi et al. have recently identified the first compounds
that target Nef [18]. The major problem is the daunting
complexity of Nef's multiple functions. Accordingly, we
will discuss four intensely studied Nef activities and assess
possible roles for each function in pathogenesis. These are
CD4 downregulation, major histocompatibility complex I
downregulation, activation of p21-activated protein
kinase (Pak2), and enhancement of virion infectivity [19].
Each function is genetically separable from the others and
therefore represents a distinct target for inhibiting Nef
[20,21]. That each of these four functions is mechanisti-
cally distinct implies that an anti-Nef drug will not be able
to debilitate Nef in general, but probably block only one
or two. This makes it imperative to determine the Nef
function most relevant to pathogenesis. In addition, we
will discuss the possibility of a radical new approach to
viral pathogenesis based on the recent model of simian
and human lentivirus pathogenesis being controlled by
the downregulation of CD3 by Nef [22]. Finally, we will
conclude that an attenuated virus vaccine based solely on
a Nef deletion is still remote, and that CD4 downregula-
tion is the most promising target for attacking HIV-1
through Nef.
Nef and disease progression
Nef was first shown to be a major determinant of primate
lentivirus pathogenicity when it was demonstrated that a
large deletion in the nef gene greatly reduces the severity
of simian immunodeficiency virus (SIV) induced disease
in rhesus macaques. Furthermore, following intravenous
injection of macaques with an SIV encoding a nef gene
with a premature stop codon, the nef open reading frame
(ORF) was rapidly restored. This demonstrated that there
was significant selective pressure to express the SIV Nef
protein [23]. HIV-1 Nef also has a key role in pathogene-
sis. There are four separate examples of LTNPs infected
with nef-deleted HIV-1. As indicated above, the best stud-
ied is the Sydney Blood Bank Cohort [15]. Infection
occurred in the short time frame between the appearance
of HIV-1 in Australia and the institution of HIV-1 blood
testing. A single donor contributed multiple units of con-
taminated blood. Red cells or platelets from that blood
were given to ten patients with eight of these recipients
becoming infected [24]. The high rate of infection is com-
parable to the rate of transfusion-associated HIV-1 infec-
tion in general which is approximately 60% [25]. This is a
striking result since the blood contributed by the donor in
the SBBC carried low levels of nef-defective virus. Clearly,
Nef is not required for transmission by blood, but is a cru-
cial factor for disease development. It is important to note
the rarity of blood transfusion related infections by nef-
deleted HIV-1s. Only one other case has been reported- a
hemophiliac infected by a Factor VIII preparation contam-
inated with HIV-1 [12] compared to the 12,000 transmis-
sions through the blood supply in the United States
alone [25].
Though Nef is not required for blood to blood transmis-
sion it appears to be an important factor for sexual trans-
mission. This is shown by the fact that there are only four
reported cases of non-transfusion related infections by
Nef-defective virus. These are the donor in the SBBC
cohort who was a sexually active homosexual male [11], a
homosexual male from Italy [14], and a male who con-
tracted a nef defective virus heterosexually in Thailand and
then transmitted the virus to his wife [13]. The virus from
all SBBC recipients and three of the four just mentioned
sexual transmissions exhibit a surprising convergence.
They all have two similar defects in the nef gene. First, the
coding region of Nef from near the initiation codon to
near the 5' end of the polypurine tract (ppt) is deleted.
Second, there is a large deletion from just downstream of
the ppt to the end of Nef but not into the major promoter
elements of U3. The simple explanation for these genetic
convergences is that the two described regions have no
major functions other than to code for Nef, and in theRetrovirology 2008, 5:84 http://www.retrovirology.com/content/5/1/84
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absence of Nef function a slight advantage is accrued to
replication by completely deleting them. The one excep-
tion was the male who contracted AIDS in Thailand. This
subtype E virus exhibited a wide range of Nef sequences
from intact to large deletions including the ppt. Blood
samples from the time of HIV-1 transmission to his wife
are not available [13] to explain how she came to be
infected with the double deleted Nef just described.
Death as a result of AIDS has not been observed in any of
the people infected by Nef-deleted virus, but in some cases
it was apparent that disease was advancing. There are 6
SBBC patients (C49, C64, C135, C54, C98, D36) whose
HIV-1 infections have been extensively documented.
Three recipients- C49, C64, and C135- lived over 20 years
without any sign of disease. Virus was not detectable in
blood from these patients, and they exhibited minimal
antibody responses [26]. Therefore, these patients are
"elite" long term non-progressors. Three additional
patients had detectable viral loads and an eventual decline
in CD4+ T cells in blood after 17 or more years of being
infected. C54 died of non-AIDS causes before the decline
in CD4+ T cells necessitated anti-retroviral drugs. C98's
CD4+ T cells declined to nearly 200 cells/ml, and received
anti-viral therapy for 16 months before dying of non-
AIDS causes. The blood donor of the cohort, D36,
declined after 18 years to 160 CD4+ T cells/ml and devel-
oped HIV-associated dementia [27]. At the point of com-
mencing therapy his plasma HIV-1 RNA was 9900 copies/
ml and there were over 750,000 copies/ml in cerebrospi-
nal fluid. One month after receiving therapy plasma viral
load was undetectable and CD4+ T cell levels increased
[28].
These last three patients are best described as slow pro-
gressors (SP). Another SP was the above mentioned
hemophiliac infected through a contaminated Factor VIII
preparation [12]. This individual was one of 7 LTNPs out
of a study group of 128 infected hemophiliacs [29]. PCR
screens for full length Nef genes yielded only this patient
as having a doubly truncated Nef. For about 10 years post-
infection his CD4+ T cell counts were stable, but after
another 3 years his CD4+ T cell count fell to 261 and
HAART was initiated [30]. An additional case of a LTNP is
an Italian homosexual whose CD4+ T cell levels have not
altered in 20 years of infection and whose viral loads have
been steady at the extremely low value of about 200 cop-
ies/ml. As previously mentioned Nef sequences derived
from this person's virus contained two deletions in Nef
upstream and downstream of the ppt [14]. Nine years
later the entire HIV-1 genome from this individual was
sequenced. Surprisingly, sequence of the env gene, but not
gag, pol, vif, vpr, tat or rev, also showed large deletions
[14,31]. Large deletions in genes other than nef have not
been seen in the SBBC [32]. Finally, the husband and wife
that are infected with a nef-deleted subtype E virus also
appear to be LTNPs. They have not shown any signs of dis-
ease progression but they may not have been infected
longer than 10 years [13].
Summarizing these studies it is evident that in vivo Nef is
a critical factor in HIV-1 replication, but it is not abso-
lutely necessary. Despite patients infected with nef-defec-
tive HIV-1 having little or no virus in their blood some did
progress towards HIV-1 disease. What percentage of HIV-
1 infected individuals have nef-deleted virus is difficult to
estimate since without disease progression many cases
could go undetected. If the percentage were anything
other than extremely low, one would certainly expect
many more cases to have been uncovered. The same argu-
ment applies to the transmission of nef-defective HIV-1
sexually. For example, the HIV-1 positive status of the hus-
band and wife pair was revealed as a result of testing dur-
ing pregnancy [13]. Therefore, it would seem that Nef is
not only a pathogenic factor but also a sexual transmis-
sion factor.
Which Nef functions are required for pathogenesis?
Nef is a small protein devoid of enzymatic activity. It is
polymorphic in length (200–215 amino acids) with the
most common length being 206 [33]. It is myristoylated
and mainly localized in the paranuclear region with
reduced expression at the plasma membrane. It serves as
an adaptor protein to divert host cell proteins to aberrant
functions that amplify viral replication [34,35]. Four in
vitro activities of HIV-1 Nef have been extensively docu-
mented. They are: 1) Nef downregulates cell surface levels
of CD4 [36-40]; 2) Nef downregulates cell surface levels of
major histocompatibility class I (MHCI) molecules [41-
45].; 3) Nef mediates cellular signaling and activation [46-
49]; and 4) Nef enhances viral particle infectivity by CD4
independent mechanisms [50-55].
Each of these four Nef functions could serve as contribu-
tors to Nef's elusive role in replication and pathogenesis.
Several reports have suggested the importance of remov-
ing CD4 from the surface of infected cells for the produc-
tion of infectious HIV-1 particles [39,56]. Without this
Nef function host cell CD4 can bind to Env during virion
budding and interfere with the production of fully infec-
tious particles. Also, Nef's ability to down-modulate
MHCI molecules could facilitate HIV-1 immune evasion
and thus enhance virus replication [57,58]. A third possi-
ble Nef-mediated enhancement of pathogenesis is cellular
activation of cell signaling pathways that could enhance
replication in partially stimulated T cells. For example, if
Nef functions in vivo to elevate the activation level of cer-
tain partially activated T cell populations then viral pro-
duction in those cells would be increased [59,60]. Of
particular interest in this regard are the memory T cells inRetrovirology 2008, 5:84 http://www.retrovirology.com/content/5/1/84
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the gut that are early targets of HIV-1 and SIV infection,
even though they lack expression of classic T cell activa-
tion markers [61-63]. Finally, the well documented Nef-
dependent enhancement of the infectivity of viral parti-
cles would be expected to accelerate the spread of virus in
vivo. This function of Nef is distinct from the role that CD4
downregulation can play in the production of competent
HIV-1 virions. These four Nef functions will now be dis-
cussed in greater detail.
A. CD4 down-modulation by Nef
The first and most extensively characterized function of
Nef is its ability to dramatically reduce the steady state lev-
els of CD4 on the cell surface [38,64])) Human CD4 is
downmodulated by Nefs from HIV-1 groups M, N, and O,
and simian immunodeficiency virus from chimpanzees
(SIVCPZ) [65], in multiple mammalian cell types [37,66],
and even in Drosophila S2 cells [67]. As mentioned above
the major role for this Nef activity may be in overcoming
the detrimental effects of high cellular CD4 expression in
the producer cell [39,68,69].
Nef-induced CD4 down-modulation involves the inter-
nalization of surface CD4 followed by degradation via the
endosomal/lysosomal pathway (Figure 1, Red). Consist-
ent with this mechanism Nef localizes to clathrin-coated
pits [70] and increases the number of CD4 containing
clathrin coated pits [71] Inhibition of lysosomal acidifica-
tion blocks Nef induced CD4 degradation, without restor-
ing CD4 surface expression [72-74] Moreover, Nef
induced CD4 downmodulation is blocked by transdomi-
nant-negative dynamin-1 co-expression [75], as well as,
pharmacological inhibitors of clathrin coated pit medi-
ated endocytosis [74].
The heterotetrameric clathrin-associated adaptor protein
2 (AP-2) is a key molecular mediator of Nef induced CD4
downmodulation [76], but other aspects of CD4 down-
regulation remain unclear. Unlike CD4 downmodulation
by phorbol esters, Nef-induced downmodulation is inde-
pendent of the phosphorylation of serine residues in the
CD4 cytoplasmic tail [38]. Data suggest that Nef may act
as a connector between CD4 and the cell's endocytic
machinery [40], by binding the membrane proximal seg-
ment of the cytoplasmic domain of CD4 [37,38,77] Fur-
thermore, NMR analysis confirms that the membrane
proximal segment of CD4 is necessary for a direct interac-
tion with Nef [78] Nef residues W57 and L58 are predicted
by NMR to be critical in this interaction and have also
been functionally demonstrated to be important for CD4
downmodulation [79]. The possible significance of this
proposed interaction between Nef and the cytoplasmic
tail of CD4 is obscured by the fact that it is weak, but the
interaction of p56lck and CD4 is strong and the p56lck-CD4
complex is not subject to rapid endocytosis [80,81] Fur-
ther, it is unlikely that Nef binds directly with p56lck intra-
cellularly [82], even though Nef has been shown to induce
endosomal accumulation of Lck [83]. This latter effect of
Nef on Lck does not appear to be related to CD4 downreg-
ulation since the L164A/L165A mutant of Nef alters the
intracellular distribution of Lck but fails to downregulate
CD4 [83,84]. An alternate model to the direct binding of
Nef to the cytoplasmic tail of CD4 has been proposed by
Coleman et al. in which Nef disregulates endosomal traf-
ficking [85].
In contrast to the poorly defined direct interaction of Nef
with the cytoplasmic tail of CD4 the direct interaction of
Nef with AP-2 has been described in detail [76]. AP-2
binds to the just mentioned dileucine motif in Nef which
is found in a structurally flexible loop that extends from
amino acids 148 to 180 [86]. The dileucine motif in Nef
exhibits a canonical 160EXXXLL165 sequence but it is not
sufficient to account for the binding of Nef to AP-2. Also
required are two acidic residues within the loop, 174(E/
D)D175. Mutation of either the dileucines or the diacidic
residues to alanines disables Nef binding to AP-2 in yeast
three hybrid assays (Nef/AP-2α/AP-2σ2) and the CD4
downregulation function. In the absence of the diacidic
residues there is weak binding by the dileucine motif
because of a suboptimal sequence for the XXX residues
(i.e. N, T and S). Replacing 161NTS163 within the Nef dileu-
cine motif with residues from the AP-2 interacting pro-
tein, tyrosinase, gives 160ERQPLL164  which even in
combination with the 174AA175 mutation binds strongly to
AP-2. The arrangement of a weak dileucine motif which is
apparently stabilized by nearby acidic residues may be
peculiar to Nef. This led Lindwasser, et al. to suggest the
Nef/AP-2 interaction as a possible target for anti-virals to
counter the pathological effects of HIV-1 [76]. The possi-
bility that blocking CD4 downregulation could have a
positive impact on HIV-1 pathogenesis is supported by
the example of an LTNP infected by a HIV-1 with a
uniquely defective Nef. Carl et al. reported a non-progres-
sor (12 years without a decline in CD4+ T cells, but rela-
tively high viral loads of 15,000 to 55,000 copies/ml) with
a small deletion in Nef and a compensating duplication
[87]. The virus in this patient had a deletion of 36 base
pairs (amino acids 26–37) and a 33 base pair duplication
(amino acids 43–53). In vitro studies demonstrated that
the deletion by itself inactivates CD4 downregulation,
enhancement of infectivity, MHCI downregulation, and
partially destabilizes the protein. Incorporating the dupli-
cation into the deletion bearing Nef gave a partially func-
tional protein that had restored enhancement of
infectivity, MHCI downregulation, and protein expression
but remained defective for CD4 downregulation. The sug-
gestion from this one patient is that an HIV-1 lacking a
Nef functional for CD4 downregulation is greatly reduced
in its pathogenic potential. Therefore, Nef-mediated CD4Retrovirology 2008, 5:84 http://www.retrovirology.com/content/5/1/84
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downregulation appears to be a potential target for anti-
viral intervention, except that the flexible structure of the
loop containing 160EXXXLL165 and 174(E/D)D175 may not
allow for the modeling of small molecules with high affin-
ity and specificity [18]. Therefore, the potentially unique
Nef-binding surface of AP-2 may be a better target.
B. MHC class I down-modulation by Nef
Another well conserved property of Nef is its ability to
downmodulate MHC class I molecules [44]. As Nef is
expressed early after infection, Nef induced downmodula-
tion of MHC class I molecules could enable the infected
cell to evade destruction by the immune system during
active viral replication. In support, it has been demon-
strated that Nef expression reduces the susceptibility of
HIV infected cells to cytotoxic T lymphocyte (CTL) medi-
ated lysis in vitro [57,58]. Therefore, determining the
mechanism by which Nef downregulates MHCI has
received a high priority. Early aspects of this field have
been reviewed [88].
Diagram illustrating the functions of Nef discussed in the text Figure 1
Diagram illustrating the functions of Nef discussed in the text.Lower right (Red), Nef removes CD4 from the cell sur-
face. Two processes are shown. To the right Nef is attached to the plasma membrane through its myristoyl group (squiggle) 
and is detaching Lck from the cytoplasmic tail of CD4. As indicated by "?" both the site and mechanism of this process are 
unknown and may be indirect. To the left Lck has been disassociated from the cytoplasmic tail of CD4 and Nef is attached to 
the plasma membrane by its myristoyl group and the cytoplasmic tail of CD4. AP-2 binding facilitates the formation of a clathrin 
coated pit that leads to the internalization of CD4. Left (Yellow), Nef downregulates MHCI from the surface of the infected cell. 
Nef binds to the cytoplasmic tail of MHCI (triple line) and AP-1 in the TGN to divert MHCI from the default pathway to the 
plasma membrane. Top (Orange), Nef activates Pak2. The identities of the other protein(s) in the Nef/Pak2 complex are not 
known as shown by the unidentified protein (?). The cellular site of the activation is also not known though the plasma mem-
brane has been proposed. Center (Pink), Nef binds to and activates Hck. The central (cytosolic) location of Nef bound to Hck 
with no attachment of the myristate to a membrane indicates that the activation of Hck is the only Nef function that does not 
require this post-translational modification. Upper right (Blue), Nef enhances the intrinsic infectivity of the HIV-1 virion. Three 
proposed mechanisms that limit HIV-1 infectivity, but are overcome by Nef are presented. The top virion fusing with the cell 
membrane is attempting to insert the viral core into the target cell but the entry of the core is blocked by cortical actin. The 
lower virion entering the cell is able to efficiently pass through the cortical actin but is subject to proteosomal degradation 
upon entry. The extracelluar virion is being prevented from attaching to the target cell by the presence of an unknown protein 
(X) that prevents Env (O) binding to target cell CD4.Retrovirology 2008, 5:84 http://www.retrovirology.com/content/5/1/84
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A long standing model proposed by Thomas and co-work-
ers [89,90] has been recently revised [41]. In this model
Nef initiates MHCI downregulation by interacting with
PACS-2. The Nef/PACS-2 complex localizes to the trans-
Golgi network (TGN) where PACS-2 is displaced and Nef
binds to a src family kinase (SFK). The SFK would then
bind and phosphorylate ZAP70/Syk on tyrosine enabling
ZAP70/Syk to bind the SH2 domain of phosphatidyli-
nositide 3-kinase (PI3K). The resulting activation of PI3K
would lead to elevated PIP3, stimulation of the guanine
nucleotide exchange factor ARNO, and GTP loading of
ARF6. At this point the rate of MHCI endocytosis is accel-
erated. For the increased rate of MHCI internalization to
be effective in reducing MHCI cell surface levels Nef must
also block the recycling of MHCI back to the plasma
membrane. The revised model does not define an interac-
tion between MHCI and Nef, but the suggestion was made
that Nef induces PACS-1 to interact with the cytoplasmic
tail of MHCI [41]. However, a ternary complex between
Nef, the cytoplasmic tail of MHCI and AP1 has been
recently demonstrated separately by the Collins and the
Guatelli laboratories [43,45]. This complex appears to
activate a cryptic tyrosine sorting signal in the cytoplasmic
tail of MHCI and diverts newly synthesized MHCI mole-
cules from their transit to the plasma membrane to an
internal compartment in the paranuclear region
[43,45,91]. Nef appears to be acting as a facilitator since
the cytoplasmic tail of MHCI does not bind to AP-1
[43,45]. How the model of Thomas and co-workers can be
adapted to include this complex is as yet unresolved (Fig-
ure 1, Yellow). It is interesting to note that this ternary
complex engages Nef in a novel interaction with MHCI
cytoplasmic tail and AP-1 which makes it potentially
appealing for targeting by an anti-viral.
However, it should be noted that Nef does not render
infected cells completely protected from immune surveil-
lance as there is a strong CTL response to HIV antigens
[92]. Therefore, it appears that the downregulation of
MHCI by Nef fails to block the cytotoxic T cell response to
the virus, but the immune response is either misdirected
or HIV-1 is able to escape by mutation or both [93]. At this
point the concept of viral evolution and its relationship to
viral pathogenesis should be considered. That there are
constraints placed on the virus by the cytotoxic T cell
response is clear if the virus mutates to avoid the response
[94,95]. This does not necessarily imply that the targeted
HIV-1 or the HIV-1 bearing escape mutation(s) are differ-
ent in pathogenic potential. In fact, Brumme et al. [94]
found an inverse relationship between the number of
apparent escape mutations in Nef and the level of CD4+ T
cells in the blood. In other words, virus with a Nef con-
taining 11 or more escape mutations was more patho-
genic than virus with a Nef containing 0–2 mutations.
This distressing finding likely reflects Nef having success-
fully evolved to readily side-step the vast majority of CTL
responses. Nef has 63 very highly conserved residues out
of 206 (99% identity), but they are scattered throughout
the protein so that no more than five are in a row [33]. As
a result, susceptible epitopes in Nef mutate at variable res-
idues to effectively escape CTLs, but Nef function is not
affected.
A relatively small number of HLA epitopes in HIV-1 genes
other than Nef have been reported that do involve escape
mutations that reduce virulence. These epitopes have been
suggested as the basis for a therapeutic vaccine [95].
Although Nef amino acid sequences are doubtful contrib-
utors to the proposed vaccine an inhibitor of Nef's ability
to downregulate MHCI could enhance the effectiveness of
such a vaccine. In this regard the Italian male infected with
a virus lacking nef subsequently evolved a virus with both
a deleted nef and env. Calugi et al [31] interpreted this
finding as an inability of the Nef deleted virus to protect
itself from CTL attack. Unfortunately, this patient appears
to be unique as the SBBC researchers did not find evidence
of the development of deletions in other genes [32].
C. Cellular activation and signaling by Nef
Disease progression may be directly associated with T cell
activation [96,97]. It is also possible that Nef may regulate
cellular activation through several kinases including Pak2
[48,49]. and Hck [82,98]. Pak2 is the best characterized
Nef-activated kinase. It has been demonstrated that Nef
activation of Pak2 leads to merlin phosphorylation at ser-
ine 518 though it has yet to be demonstrated that HIV-1
infection is in anyway dependent on merlin phosphoryla-
tion [46]. The obvious suggestion of this result that Nef
regulates the actin cyotskeleton function is appealing, but
the mechanism is controversial [99-102].
Substantial agreement exists that Nef forms a complex
with Pak2 (Figure 1, Orange) [65,100,103,104]. Nef not
only complexes with Pak2 but also induces Pak2 activa-
tion [49,105] The ability of Nef to activate Pak2 in multi-
ple HIV-1 subtypes suggests a key role for this Nef
function [33,106]. An interaction domain that is respon-
sible for Pak2 activation has been observed to include res-
idues 89 and 191 [33]. Lesser contributions are made by
residues 85 and 188 [103,106,107]. Remarkably, H89 and
F191 are highly conserved in subtype B Nefs, but in sub-
type E Nefs F89 and R191 are highly conserved instead
[33]. Since subtype E Nefs are active for Pak2 activation it
appears that at least two different interaction domains are
functional in HIV-1 Nefs. By substituting all four just
mentioned residues in a subtype B Nef with residues that
predominant in subtype E Nefs (L85F, H89F, R188A, and
F191R) the subtype E Pak2 interaction surface can be cre-
ated in a subtype B background. The quadruple mutant is
fully functional though intermediate forms are generallyRetrovirology 2008, 5:84 http://www.retrovirology.com/content/5/1/84
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defective [33]. The significance of these alternate Pak2
activation domains remains to be determined. However,
the presence of different structures to achieve the same
function strongly suggests that maintaining the ability to
activate Pak2 enhances viral fitness. The importance of
Pak2 activation has been questioned on the basis of ex vivo
experiments [108]. One possibility is that Pak2 activation
may be important for transmission or early in infection.
However, only limited evidence currently exists to support
this hypothesis [21]. Regardless, the structural fluidity of
Nef's Pak2 interaction surface could make this Nef inter-
action difficult to target with anti-virals. Investigations to
uncover the common features of the alternative activation
domains may clarify these issues.
Nef also activates the myeloid lineage specific tyrosine
kinase, Hck (Figure 1, Pink). Co-expression of Nef and
Hck in Rat-2 fibroblasts leads to cellular transformation
[109]. Moreover, Nef tightly binds to the Hck SH3
domain in vitro and activates its kinase activity [110]. In
Rat-2 cells enforced dimerization of Nef enhances Hck
activation [98]. Nef has also been shown to modestly acti-
vate endogenous Hck and, in turn, the Stat3 transcription
factor in myeloid cells [111]. Interestingly, Hck is the only
cellular activity of Nef known to not require Nef myris-
toylation [111]. The Hck/Nef interaction is mediated by
an SH3 binding domain in Nef 72PQVPLR77 which may be
too similar to cellular SH3 interactions to be readily tar-
geted by an anti-viral. On the other hand, one distinctly
virus-specific interaction would be Nef dimerization
which may be required for Hck activation intracellularly.
In fact, Nef spontaneously forms dimers and trimers
[112]. This may occur when the myristate moiety is buried
in a cellular membrane. Disengagement from membrane
appears to result in the myristoylated N-terminus of Nef
self-associating with a hydrophobic patch on the surface
of the structured core of Nef. In this latter conformation
Nef is a monomer. Therefore, Nef lacking its N-terminal
myristate may dimerize and activate Hck. The relevance of
Hck activation for pathogenesis is unknown, but if Nef
dimerization and trimerization are of pathological signif-
icance it could be a novel target for anti-virals.
D. Enhancement of HIV-1 infectivity
Early work on this topic has been previously reviewed
[88]. Currently, there are three models of how Nef
enhances the infectivity of HIV-1 as measured in single
infection assays [50,54,113,114]. In these assays virus is
produced in cells that do not express CD4 and the nor-
malized infectivity is determined on indicator cell lines.
Therefore, this effect represents increased infection effi-
ciency for HIV-1 virions, and is distinct from Nef-depend-
ent enhanced particle egress from infected macrophages
[115]. Campbell et al. noted that the disruption of the
actin cytoskeleton in the target cell complemented the
defect in infectivity in Nef minus virions (Figure 1, Blue).
These authors concluded that cortical actin represents a
barrier to infection and that the expression of Nef in the
producer cell is able to overcome this barrier [54]. In an
alternate model Pizzato et al. suggest that there is an
unknown cellular protein other than CD4 that blocks the
function of Env in the virion. Nef enhances infectivity by
downregulating this unknown protein in the producer
cell and blocking its incorporation into the virion [50]. It
is interesting to note that the Nef dileucine motif
(164LL165) that is required for CD4 downregulation is also
required for enhancement of infectivity [116]. However,
the diacidic motif (174DD175) that is necessary for Nef to
bind AP-2 is not. This genetically distinguishes enhance-
ment of infectivity from CD4 downregulation. In this case
it appears that Nef's canonical dileucine binding motif
involving E160 (160EXXXLL165) associates with AP-1 and
AP-3 [85,116,117]. It is not yet known if these results are
related to the above mentioned results of Pizzato [50].
Finally, Nef may protect the viral core from post-fusion
degradation to allow reverse transcription to proceed
[113,114]. This mechanism is consistent with the active
degradation of HIV-1 virions that occurs upon entry
[118]. Despite the attractiveness of a drug that reduces the
inherent infectivity of HIV-1 virions the prospects for
inhibiting Nef-mediated enhancement of infectivity are
presently remote.
E. Downregulation of CD3 as a mechanism of attenuating viral 
pathogenesis
Schindler et al. have proposed a surprising explanation for
the lack of pathologic effects of most primate lentiviruses
in their hosts in contrast to the virulence of HIV-1. Specif-
ically, it was proposed that most simian viruses self-limit
their inherent pathogenicity [22]. For example, sooty
mangabeys do not develop AIDS from their own SIV
[119,120]. Schindler et al suggest this is the result of the
SIV from sooty mangabey (SIVSM) having a Nef that
downregulates CD3 which prevents activation of the
infected T cell and subsequent activation induced cell
death. The authors further propose that the downregula-
tion of CD3 evolved as a mechanism to maintain virus
persistence in the presence of an intact host immune sys-
tem. The CD3 downregulation function was lost in chim-
panzee immunodeficiency virus (SIVCPZ) prior to the
infection of humans. Since HIV-1 Nef does not downreg-
ulate CD3 humans progress to AIDS as hyperactivation
slowly destroys the immune system. The therapeutic
implications of this concept are staggering since one must
assume that during the course of natural SIVSM infection
there are mutations in nef that abrogate CD3 downregula-
tion. The unanswered question is how these potentially
pathogenic SIVSM mutants are suppressed by the non-
pathologic virus? If such a mechanism were to be demon-
strated it may be possible to produce an HIV-1 with a NefRetrovirology 2008, 5:84 http://www.retrovirology.com/content/5/1/84
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that downregulates CD3 and therefore a dominant, non-
pathogenic virus.
A distinctly different explanation of non-pathogenicity is
that the sooty mangabey itself has a special mechanism
for suppressing the progression to AIDS not the virus
[121]. This would explain the fact that rhesus macaques
develop AIDS when directly infected with blood from an
infected sooty mangabey, but infection of virus-free sooty
mangabeys does not [119]. In other words, rhesus
macaques die even though the infecting SIVSM's Nef is
downregulating CD3. An additional example of SIVSM
being pathogenic when a species barrier is crossed is SIVSM
causing AIDS in a black mangabey [122]. Two additional
lineages of SIV including African green monkey (SIVAGM)
and sun-tailed monkey (SIVSUN) cause AIDS in pig-tailed
macaques [123,124], but not that from Sykes' monkey
(SIVSYK) [125]. Like Nef from SIVSM the Nefs from SIVAGM,
SIVSUN, and SIVSYK all downregulate CD3 [22,126]. It
should be further noted that the non-pathogenicity of
SIVSM is not absolute in sooty mangabeys. Ling et al. have
reported a 21 year old sooty mangabey which developed
AIDS [121]. These investigators suggest that the evolution-
ary adaptation to SIVSM is one of delayed progression
beyond the usual lifespan of the animal which for sooty
mangabeys is under 20 years. In the future it will be
important to demonstrate SIVSM and/or SIVAGM specifi-
cally defective in CD3 downregulation are significantly
pathogenic in their natural hosts.
Schindler et al. have generalized the hypothesis that CD3
downregulation prevents lentivirus pathogenesis by
investigating human immunodeficiency virus 2 (HIV-2)
[22]. HIV-2 is a zoonotic virus derived from sooty mang-
abeys [127]. It has reduced pathogenicity relative to HIV-
1 overall, but progression to AIDS can occur [128]. Con-
sistent with reduced pathogenicity HIV-2 Nefs do down-
regulate CD3 [129], but in the cases in which HIV-2
infection has progressed to AIDS one would expect that
Nefs derived from these patients would not be functional
for CD3 downregulation. This is not the case for Nefs
from HIV-2ROD, HIV-2BEN, and HIV-2CBL23 which all came
from symptomatic patients and all downregulated CD3
[129]. The pathogenic phenotype of HIV-2 can also be
observed in rhesus macaques [130,131]. To demonstrate
that CD3 downregulation can block disease progression
in humans it will be important to thoroughly investigate
the relationship between HIV-2 AIDS and CD3 downreg-
ulation.
That a given species may be resistant to its own lentivirus
without involvement of CD3 downregulation is clearly
demonstrated by the non-pathogenic nature of SIVCPZ. In
the case of chimpanzees the downregulation of CD3 can-
not serve as a mechanism for non-pathogenicity since
SIVCPZ Nef does not downregulate CD3 [22]. Humans lack
the ability that chimps have to resist the chimpanzee virus
and develop AIDS. Finally, there is evidence that virus
with the capacity to downregulate CD3 can not delay HIV-
1 pathogenesis. This is suggested by the cases of dual HIV-
1/HIV-2 infection. Despite the ability of HIV-2 Nef to
downregulate CD3 these patients suffer the greater viru-
lence of HIV-1 [132]. Therefore, it would appear that the
non-pathogenic phenotype attributed to Nefs that down-
regulate CD3 is not dominant over the pathogenic pheno-
type in humans.
Overall, we conclude that at present there are minimal
prospects for therapeutic insights resulting from the attri-
bution of HIV-1 pathogenicity to the inability of HIV-1
Nef to downregulate CD3. If this proposal is to be devel-
oped further, it will be necessary to molecularly define the
structural correlates of CD3 downregulation. Then the
determination could be made if HIV-1 with a Nef modi-
fied to downregulate CD3 has reduced pathogenesis in
the humanized mouse model [133]. Alternatively, the
pathogenesis of HIV-2s with and without the ability to
downregulate CD3 could be evaluated for virulence in
humanized mice.
Attenuated vaccines
The mechanism of adaptation to SIVSM by sooty manga-
beys suggested by Ling et al. [121] is analogous to the
approach taken for highly active antiretroviral therapy.
Ideally, SIVSM and HIV-1 infections are restrained to be
sufficiently chronic and long-lasting that progression to
AIDS fails to occur in the life time of the host. This
approach is decidedly less desirable than an effective vac-
cine. Unfortunately, standard vaccine approaches are
proven failures. The viral Env has evolved to a highly com-
plex structure that in its native form resists antibody rec-
ognition [134]. Broadly neutralizing antibodies (BNAB)
do develop during HIV-1 disease that recognize highly
conserved epitopes in Env [10], but Env escape variants
develop [135,136]. The best hope for preventing HIV-1
infection would be if an attenuated vaccine were to yield
BNAB prior to infection. This would allow the immune
system to attack the virus early in infection when it is most
vulnerable. One positive aspect of the study of the SBBC
is that the slow progressors D36, C54, and C98 were able
to produce BNAB [15,26]. Unfortunately, these are the
three patients that demonstrated disease progression. The
LTNPs C49, C64, and C135 had little or no BNAB activity
in their blood. So we don't know if C49, C64, or C135
were "immunized" against HIV-1. Therefore, despite mas-
sive efforts to understand the "natural immunization" of
SBBC patients with nef-deleted virus there is little evidence
that this type of attenuated virus can be effectively or even
safely employed.Retrovirology 2008, 5:84 http://www.retrovirology.com/content/5/1/84
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The progression of D36, C54, and C98, and the failure of
C49, C64, and C135 to maintain BNABs have been ration-
alized by the threshold hypothesis [132]. The divergent
patient responses to being exposed to an attenuated virus
result from multi-factorial host-virus dynamics. A sero-
conversion threshold may be reached by a certain level of
viral replication, but vaccine protection fails to develop.
Conversely, the vaccine threshold may be surpassed
resulting in disease development if viral replication is too
active. Thus, development of an attenuated virus that can
with virtual certainty yield the correct level of replication
for non-pathogenicity but still induce a significant and
long-lived immune response in the majority of recipients
may not be possible. In 1994 the World Health Organiza-
tion emphasized the importance of determining the opti-
mal combination of genes that could be deleted to ensure
safety of an infectious attenuated HIV-1 vaccine [137].
The complexity of defining such a combination of genes
is indicated by the report of Churchill et al. [138] that fur-
ther characterized the two SBBC cohort members that pro-
gressed to the point of HAART treatment. The virus from
slow progressor, D36, was partially defective in rev, but
slow progressor C98 had a fully functional rev. Therefore,
the a second defective gene in addition to nef may not reli-
ably further attenuate the virus. As knowledge of the func-
tions of Vif and other HIV-1 accessory proteins grows
superior schemes involving combinations of inactivated
genes may become apparent for attenuating HIV-1.
Conclusion
Anti-HIV-1 drugs rapidly become ineffective unless
administered in multi-drug combinations. More drugs
attacking multiple aspects of the viral replication cycle
and especially transmission are needed to treat and pre-
vent HIV-1 infection. The enzymatic activities reverse tran-
scriptase and protease have been attacked by anti-virals,
but developing drugs that target novel interactions
between viral and host cell proteins will be more difficult.
Nonetheless, given the relentless nature of HIV-1 all rea-
sonable possibilities should be considered. For Nef the
downregulation of CD4 appears to be the most promising
function to disrupt by an anti-viral. Evidence in hand indi-
cates this approach has the distinct potential to blunt HIV-
1 pathogenesis. MHCI downregulation is more problem-
atic despite a novel Nef/host cell protein-target interaction
because blocking this function may not significantly
impact pathogenesis. However, an anti-Nef drug targeting
MHCI downregulation may enhance the ability of a CTL-
directed therapeutic vaccine. Pak2 activation may be par-
ticularly difficult to target and enhancement of virion
infectivity is insufficiently understood to even know what
to target.
In a recent development Betzi et al. have identified drug-
like compounds (D1 and DCL27) that interact with the
SH3 binding domain of Nef [18]. D1 has been observed
to interfere with the binding of Hck to Nef, weakly inhibit
MHCI downregulation, but have no effect on CD4 down-
regulation. The effect of D1 on MHCI downregulation
may be the result of the proximity of the SH3 binding
domain 72PQVPLR77 to P78 which is crucial for formation
of the ternary complex formed between Nef, the cytoplas-
mic tail of MHCI, and AP-1 [43,45]. Whether D1 binds to
cellular SH3 binding domains remains to be determined.
Like progress against HIV-1/AIDS, progress in understand-
ing Nef, has been tedious and difficult, but there is no
option to continuing to acquire more knowledge about
the virus and its proteins.
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